Cinvanti (aprepitant) Disease Interactions
There is 1 disease interaction with Cinvanti (aprepitant):
Aprepitant (Includes Cinvanti) ↔ Liver Disease
Moderate Potential Hazard, Moderate plausibility
Applies to: Liver Disease
Aprepitant is primarily metabolized by the liver. In studies of patients with mild to moderate hepatic impairment (Child-Pugh score 5 to 9), aprepitant was well tolerated and no clinically significant alterations in its pharmacokinetics were observed. Thus, no dosage adjustment of aprepitant is necessary in this patient population. However, there are no clinical or pharmacokinetic data in patients with severe hepatic impairment (Child-Pugh score > 9), and caution is advised if aprepitant is used in such patients.
- "Product Information. Emend (aprepitant)." Merck & Company Inc, West Point, PA.
Cinvanti (aprepitant) drug Interactions
There are 535 drug interactions with Cinvanti (aprepitant)
More about Cinvanti (aprepitant)
- Cinvanti Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Pricing & Coupons
- Drug class: NK1 receptor antagonists
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.